

# Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

## Leiden University Medical Center Flow Cytometry Core Facility

RRID:SCR\_023903

Type: Tool

---

### Proper Citation

Leiden University Medical Center Flow Cytometry Core Facility (RRID:SCR\_023903)

---

### Resource Information

**URL:** <https://www.lumc.nl/en/research/facilities/flow-cytometry-core-facility/>

**Proper Citation:** Leiden University Medical Center Flow Cytometry Core Facility (RRID:SCR\_023903)

**Description:** Provides flow cytometers for users from the LUMC, Leiden University and external companies. Instruments include conventional and spectral analyzers, cell sorters and mass cytometers. These instruments allow analysis and sorting up to biohazard level ML-II, while one analyzer is available for ML-III material. Provides support for all aspects of cytometry, including experimental design, instrument setup, data acquisition and data analysis.

**Abbreviations:** LUMC FCF

**Synonyms:** Flow Cytometry Core Facility

**Resource Type:** access service resource, service resource, core facility

**Keywords:** USEDit, ABRF, conventional and spectral analyzers, cell sorter, mass cytometer, experimental design, data acquisition, data analysis,

**Availability:** Open

**Resource Name:** Leiden University Medical Center Flow Cytometry Core Facility

**Resource ID:** SCR\_023903

**Alternate IDs:** ABRF\_1819

**Alternate URLs:** <https://coremarketplace.org/?FacilityID=1819&citation=1>

**Record Creation Time:** 20230802T050218+0000

## Ratings and Alerts

No rating or validation information has been found for Leiden University Medical Center Flow Cytometry Core Facility.

No alerts have been found for Leiden University Medical Center Flow Cytometry Core Facility.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Groeneveldt C, et al. (2024) Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies. Cancer immunology research, 12(3), 334.